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survival as well as acute and late toxicities were 
retrospectively analyzed. 
 
Results: Brachytherapy was performed as initially planned in 
all but one patient. 18 patients had a complete endoscopic 
response at the first follow-up examination. Loco-regional 
recurrence was observed in 24 patients after a median time 
of 3 months; 1- and 2-year recurrence-free survival rates 
were 51% and 51% for the patients treated for primary tumors 
and 11% and 6% for patients treated for tumor recurrence, 
respectively. Median overall survival was 18 months; 
estimated overall survival rates at 1, 2 and 3 years were 63%, 
50% and 30% after primary brachytherapy, and 60&, 25% and 
6% after treatment for recurrent cancers. Adenocarcinoma 
histology, non-complete remission after treatment and 
treatment for recurrent cancers were associated with 
significantly reduce prognosis. Mild to moderate dysphagia 
was the most common side effect in 17 patients; 8 patients 
suffered from loco-regional grade 3 toxicities, and no grade 4 
or 5 toxicities were observed. 
 
Conclusion: Endoluminal brachytherapy during the course of 
esophageal cancer treatment can be safely applied and 
results in good functional outcomes regarding dysphagia with 
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Purpose or Objective: To describe the technique used in our 
department for treatment of cutaneous tumors with HDR 
plesiotherapy using custom moulds and to analyze long term 
results.  
 
Material and Methods: 
Custom made mould fabrication:  
We used this aplicator in irregular areas of skin.  
The treatment sequence is:  
- Creation of the mould with thermoplastic material with a 
thickness of 5 mm.  
- Parallel placement of transfer guide tubes with 1 cm of 
separation.  
- CT simulation and definition of the volume treat. The 
volume has to be delimited 5 mm in deep.  
- Dosimetry.  
- Treatment of the patient.  
We used 3 different schedules:  
- 54 Gy in 18 fractions  
- 66 Gy in 33 fractions  
- 40 Gy in 10 fractions 
 
Results: From September 2008 until September 2015 53 
patients had been treated with this technique.  
The average age was 77 years (63-91), the histology was 
squamous in 6 cases, basocellular in 46 cases, melanoma in 
situ in 1 case.  
The mean dose was 54.8 Gy (40-66). The treatment was 
adjuvant after surgery in 41,5% of the patients. 
After a mean time of follow up was 34,1 months there were 2 
local relapses (3.77%) in the treatment location. No deaths 
related to disease were observed. 
 
Conclusion: Treatment with HDR plesiotherapy using custom 
moulds is a technique used to treat small lesions and/or 
irregular surface locations. Planning with CT scan allows to 
know the dose in organs at risk using dose-volume histogram. 
This treatment offers a high local control of the disease and 
can be used alone or as adjuvant treatment after surgery in 
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Purpose or Objective: Previous literatures showed prior liver 
external beam radiotherapy (EBRT) may increase liver 
toxicity after yttrium-90 (90Y) selective internal radiation 
therapy (SIRT). In contrast, the safety of EBRT followed by 
SIRT is unclear. We investigated the safety and efficacy of 
EBRT followed by SIRT in hepatocellular carcinoma (HCC) 
patients. 
 
Material and Methods: Between October 2011 and May 2015, 
a total of 11 HCC patients who had treated with SIRT 
followed by liver salvage EBRT were enrolled. The SIRT 3-
dimensional absorbed dose distribution of each patient was 
retrospectively calculated on a voxel base, using post-
treatment bremsstrahlung SPECT/CT images. The physical 
dose and biological effective dose (BED) of SIRT and EBRT 
were generated and summed for evaluation. The dose-
volume histograms (DVHs) of the EBRT, SIRT, and combined 
therapy were analyzed. Liver-related toxicities were 
collected by chart-review and classified as Common 
Terminology Criteria for Adverse Events version 4. 
 
Results: The median time interval of SIRT and EBRT was 95 
days (IQR: 66.5-129.5 days). Eight patients (73%) had 
undergone EBRT for portal vein thrombosis (PVT) and 6 
patients (55%) for residual hepatic tumor. The mean SIRT, 
EBRT, and combined therapy normal liver BED were 
52.1±21.0 Gy, 17.9±6.1 Gy, and 69.5±15.0 Gy, respectively. 
The summed DVH of each patient is depicted in Figure 1. The 
image study three months post-irradiation showed primary 
disease PR in 4 patients (67 %) of patients and thrombosis 
improved in 6 patients (75%) after EBRT. Two patients had no 
evidence of disease after combined therapy. The median 
survival was 359.9 days. Total 3 patient (27 %) had developed 
≧grade 2 liver toxicities. Patient who experienced 
hepatotoxicity had higher summed BED (107.0±7.3 Gy vs 
58.9±13.5 Gy; P = 0.02). The univariate analysis of summed 
DVH showed that the fraction of normal liver exposed to 
more than 70 Gy (V70) was the strongest predictor of 
hepatotoxicity (9.4±7.2% vs 29.9±4.4%; P=0.007), as 
presented in Table 1.  




Table 1. Dosimetric parameter univariate analysis 




Conclusion: Salvage EBRT after SIRT was effective for HCC 
patients with PVT. The 3D dose summation and BED-DVH of 
combined therapy help to predict liver toxicity. By carefully 
selecting patients, the combined therapy bring acceptable 
toxicities incidence.  
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Purpose or Objective: Unflattened surface HDR 
Brachytherapy applicators commonly suffer from dose fall off 
on the side of the dose distribution. Recent research 
documented that in addition to missing dose at the side of 
the applicator vertical type HDR Brachytherapy surface 
applicators are subject to underdose in the middle of the 
treatment region. This artifact is clinically relevant because 
tumor cells in the middle of the treated area can end up 
irradiated insufficiently. In this work we present a surface-
dose compensation body generated with a 3D printer that 
specifically addresses the dose irregularities of a vertical 
type HDR Brachytherapy surface applicator. In order to 
overcome the limitation of increased treatment time of 
applicator flattening for horizontal type applicators we 
utilize the possibility of using a source position nearer to the 
surface to generate a flattened dose distribution together 
with reduced treatment time. 
 
Material and Methods: A 40 mm Varian VariSource 
GM11010080 applicator was used for the modification (Varian 
Medical Systems, Inc., Palo Alto, CA, USA). The source 
position is 1.5 cm from applicator tip. The depth of 
evaluation is 0.5 cm solid water material. A consumer grade 
3D printer “UP! 3D, Beijing TierTime Technology Co. Ltd.” 
was used to print out a negative form with ABS plastic. 
Lippowitz type low temperature melting metal was used to 
mold the positive form of the flattening elements. All dose 
measurements and flatness evaluations were performed with 
Gafchromic EBT3 film Lot #: 12021402 and the FilmQA 
software, flatness and symmetry toolbox (both Ashland 
Speciality Ingredients, Bridgewate, NJ, USA). 
 
Results: The generated compensation element is of toroidal 
shape, for the standard source position 1.5 cm from appliator 
tip, has a maximum thickness of 1.5 mm in surface direction. 
The output of the applicator with flattening element 
occurred to be 75% of the unflattened one. The diameter of 
80% nominal dose area increased from 35.2 mm with the 
unflattended applicator to 50.2 mm with the flattening 
element in place. The asymetric central low-dose artefact 
can be compensated to a clinical acceptable minimum dose. 
When utilizing the source position 1 cm from tip a prototype 
filter could bring the width of the 80% dose area to 45.0 mm, 
above the nominal applicator size, and output to 112 % of an 
unflattened applicator. The position 0.5 cm from tip is still 
considered flattable with increased low dose area in out of 
field tissue due to applicator geometry when quick treatment 
is of clinical interest. The first soure position on applicator 
tip is not flattable for clinical use. 
 
Conclusion: The presented prototype of a dose compensation 
body can remove the dose artefacts of a vertical type HDR 
Brachytherapy surface applicator including the clinical 
relevant underdosed central region. With the appropriate 
flattening body it is now possible to utilize a source position 
nearer to surface and compensate for dose output loss when 
using a dose flattening element. 
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Purpose or Objective: Skin cancer is the most common 
malignancy in white population. The most prevalent 
histologies are basal cell carcinoma (BCC) followed by 
squamous cell carcinoma (SCC). They are locally aggressive 
lesions that rarely metastasize and their prognosis depends 
on local control. Due to their localization and superficial 
nature, cosmetic result of the treatment is of primary 
importance. High-Dose-Rate brachytherapy (HDR-BT) is a safe 
and effective treatment option for these carcinomas and for 
other skin lesions. There are two main techniques for its 
delivery: interstitial brachytherapy and plesiotherapy.  
We have evaluated early local control, acute toxicity and 
cosmetic outcomes in all patients treated with HDR-BT in our 
center. 
 
Material and Methods: We assessed 47 patients who had 52 
skin lesions. There were 29 SCCs, 14 BCCs, 4 keloid scars, 3 
adenocarcinomas,1 lentigo maligna and 1 Merkel cell 
carcinoma. Median age of treated patients was 78 years (34-
93). Data was collected prospectively.All lesions were 
treated with HDR-BT at our institution between December 
2014 and August 2015 by interstitial brachytherapy or 
plesiotherapy. Average total dose delivered was 35,63 Gy and 
Median dose delivered was 40,5 Gy.  
Acute toxicity was graded using the Common Terminology 
Criteria for Adverse Events, version 4.0 and cosmetic 
outcomes were classified using the Radiation Therapy 
Oncology Group cosmetic rating scale. 
 
Results: Average follow-up from completion of treatment 
was 5.5 months (2-10.1). The overall crude recurrence rate 
was 3,8% (n = 2). Grade 0 acute toxicity was observed in 7.7% 
of treated lesions (n = 4), grade 1 in 63.5% (n = 33), grade 2 
in 21.2% (n = 11) and grade 3 in 7.7% (n = 4). No acute 
toxicity greater than grade 3 was observed. All acute toxic 
events were resolved between the first and the second month 
after brachytherapy. Cosmetic results were excellent or good 
in 92.3% of the cases (n = 48), fair in 3.8% (n = 2) and not 
evaluable in 2 patients whose tumours were not cured. 
 
 
